Search

Displaying results 6831 - 6840 of 8010 in total
  1. Drug

    TAK-243

    go.drugbank.com/drugs/DB15013
    Investigational

    TAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic

  2. Drug

    Tiropramide

    go.drugbank.com/drugs/DB13091
    Investigational

    Tiropramide is under investigation in clinical trial NCT01629212 (Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome).

    Categories: Drugs for Functional Gastrointestinal Disorders
  3. Drug

    SR 140333

    go.drugbank.com/drugs/DB05790
    Experimental

    SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.

  4. Drug

    Diisopromine

    go.drugbank.com/drugs/DB13476
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  5. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Categories: Heterocyclic Compounds with 4 or More Rings
  6. Drug

    Oleic monoethanolamide

    go.drugbank.com/drugs/DB16495
    Investigational

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    BB-1701

    go.drugbank.com/drugs/DB17443
    Investigational

    BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

  8. Drug

    E59

    go.drugbank.com/drugs/DB18372
    Experimental

    It was developed by Sixal Inc.

  9. Drug

    Norethandrolone

    go.drugbank.com/drugs/DB12787
    Investigational

    Norethandrolone is under investigation in clinical trial NCT00700544 (Treatment Outcome in Elderly Patients).

    Categories: Anabolic Agents for Systemic Use
  10. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid